Inherent Biosciences, Inc. Awarded NIH SBIR Phase I Grant to Commercialize Innovative Diagnosis of Non-Obstructive Azoospermia (The Most Severe Form of Sperm Dysfunction) SALT LAKE CITY, April 13, 2022 (GLOBE NEWSWIRE) -- Inherent Biosciences, a biotechnology company pioneering epigenetic medicine, today announced an award from the National Institute of Child Health...

Inherent Biosciences Launches Path Fertility - Epigenetic Sperm Quality Test (SpermQT) SALT LAKE CITY, Oct. 18, 2021 (GLOBE NEWSWIRE) --  Inherent Biosciences, a molecular diagnostics company at the intersection of epigenetics and artificial intelligence (AI), today announced the...